Cart

Cart


Research & Trial Information

SCHEMA S1418 BR006

Protocol#: SWOG – s1418  BR006

Cancer Type: Breast Adjuvant Triple Negative

 

STEP 1 REGISTRATION

  1. Patients must have histologically confirmed ER-, PR- and HER2-negative (triple negative, TNBC) with residual invasive breast cancer, as defined by the 2010 and 2013 ASCO CAP guidelines, after completion of neoadjuvant chemotherapy. Residual disease must be ≥ 1 cm in greatest dimension, and/or have positive lymph nodes (ypN+) observed on pathologic exam.NOTE: IHC-positive isolated tumor cells in the lymph node (N0 [i+]) are not considered node-positive and these patients also must have ≥ 1 cm residual invasive cancer in the breast in order to be eligible.
  2. Patients must not have metastatic disease (i.e., must be M0).
  3. It is preferred that axillary lymph node sampling is performed after completion of neoadjuvant chemotherapy to allow more accurate assessment of pathologic response. Patients must have a complete axillary lymph node dissection after neoadjuvant chemotherapy in the following situations (exceptions will be granted for patients participating in the Alliance A11202 trial):
    • Patients had documented pathologic involvement of the axillary nodes (FNA or core biopsy) before   neoadjuvant chemotherapy and had sentinel node biopsy after neoadjuvant chemotherapy with positive sentinel node(s).
    • Patient had documented pathologic involvement of the axillary nodes (FNA or core biopsy) before neoadjuvant chemotherapy and had only 1 sentinel lymph node removed after neoadjuvant chemotherapy.

    NOTE: Patients who undergo sentinel node biopsy before starting neoadjuvant treatment and do not undergo post neoadjuvant assessment of the axillary nodes or who have negative axillary nodes on post neoadjuvant assessment must have ≥ 1 cm residual invasive cancer in the breast after completion of neoadjuvant chemotherapy.

  4. Patients must have a minimum of five, available unstained slides from the residual (post-neoadjuvant) invasive tumor in primary site or lymph node to be submitted within 7 days after registration to determine PD-L1 expression as described in Section 15.1. The tumor tissue must be adequate for PD-L1 testing, which typically requires a minimum of 100 cancer cells per slide.
  5. Patients must have had neoadjuvant chemotherapy followed by surgery. The recommended neoadjuvant treatment should include 16-24 weeks of a third-generation chemotherapy regimen as recommended by NCCN guidelines for triple negative breast cancer (examples include dose dense AC followed by dose-dense paclitaxel; weekly paclitaxel x 12 followed or preceded by FAC, FEC, AC or dose dense AC; docetaxel either followed or preceded by FEC/FAC or AC. Carboplatin containing neoadjuvant chemotherapy is also allowed). Patients who cannot complete all planned treatment cycles for any reason are considered high risk and therefore, are eligible for the study if they have residual disease. Patients must have resolution of adverse event(s) of the most recent prior chemotherapy to Grade 1 or less, except alopecia and ≤ Grade 2 neuropathy which are allowed.
  6. Patients may receive post-operative (adjuvant) chemotherapy for up to 24 weeks of duration (e.g. 8 cycles of capecitabine as in the CREATE-X trial) after completion of surgery at the discretion of the treating physician. Patients must have resolution of adverse event(s) of the most recent prior chemotherapy to Grade 1 or less, except alopecia and ≤ Grade 2 neuropathy which are allowed. Adjuvant chemotherapy, if administered, must have been completed within 35 days prior to screening registration and must be given prior to radiation.
  7. Patients must have completed their final breast surgery (rendering them free from disease) with clear resection margins for invasive cancer and DCIS within 90 days prior to screening registration for patients not receiving post-operative (adjuvant) chemotherapy, or within 210 days prior to screening registration for patients who have completed post-operative (adjuvant) chemotherapy. Positive margins are allowed only if the surgical team of the patient deems further resection impossible.
  8. Patients for whom radiation therapy (RT) to the affected breast or chest wall and regional nodal areas is clinically indicated as per NCCN treatment guidelines, should receive RT after randomization when possible, concomitant with MK-3475 (pembrolizumab) if randomized to the experimental arm. However, RT administered prior to registration is also allowed. Patients must specify at the time of screening registration whether or not they will receive RT and the extent of intended RT.
  9. Patients must not have had prior immunotherapy with anti-PD-L1, anti-PD-1, anti-CTLA4 or similar drugs. Patients must not be planning to receive any of the prohibited therapies listed in Section 7.3 during the screening or treatment phases of the study.
  10. Patients must not be planning to receive concomitantly other biologic therapy, hormonal therapy, other chemotherapy, surgery or other anti-cancer therapy except radiation therapy while receiving treatment on this protocol.
  11. Patients must be women or men ≥ 18 years of age.
  12. Patients must have Zubrod Performance Status ≤ 2.
  13. Patients must not have a history of (non-infectious) pneumonitis that required steroids or evidence of active pneumonitis.
  14. Patients must not have an active infection requiring systemic therapy.
  15. Patients must not have active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  16. Patients must not have received live vaccines within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, BCG, and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed
  17. Patients must not have known active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection prior to registration. Patients who have completed curative therapy for HCV are eligible. Patients with known HIV infection are eligible if they meet each of the following 3 criteria:
    • CD4 counts ≥ 350 mm3
    • Serum HIV viral load of < 25,000 IU/ml and
    • Treated on a stable antiretroviral regimen.
  18. No other prior invasive malignancy is allowed except for the following: adequately treated basal (or squamous cell) skin cancer, in situ breast or cervical cancer. Stage I or II invasive cancer treated with a curative intent without evidence of disease recurrence for at least five years.

STEP 2 REGISTRATION (Randomization)

  1. Patients must not be registered to Step 2 until receiving confirmation from the SWOG Statistical Center that the patient’s tissue specimen was adequate for PD-L1 testing. Patients must be registered within 7 days of receiving the e-mail notification confirming submission was evaluable for PD-L1 status.
  2.  A serum TSH must be obtained within 28 days prior to Step 2 registration to obtain a baseline value.
  3. Patients must have adequate bone marrow function as evidenced by all of the following: ANC ≥ 1,500 microliter (mcL); platelets ≥ 100,000/mcL; Hemoglobin ≥ 9 g/dL.
  4. Patients must have adequate hepatic function as evidenced by the following: total bilirubin ≤ 1.5 x institutional upper limit of normal (IULN) (except Gilbert’s Syndrome, who must have a total bilirubin < 3.0 mg/dL), and SGOT (AST) or SGPT (ALT) and alkaline phosphatase ≤ 2.5 x IULN.
  5. Patients must have adequate renal function as evidenced by ONE of the following: serum creatinine ≤ IULN OR measured or calculated creatinine clearance ≥ 60 mL/min.

 

 



Research & Trial Information

SCHEMA E1A11

Protocol#: ECOG – EA1131

Cancer Type: Breast Adjuvant Triple Negative

 

Eligibility Criteria for Screening and Molecular Profiling (STEP 0)

  1. Age ≥ 18 years.
  2. ECOG Performance Status 0 or 1 within 2 weeks prior to screening.
  3. Female and male patients must have histologically confirmed triple negative (ER-/PR-/HER2-) invasive breast cancer, clinical stage II-III at diagnosis based on initial evaluation by clinical examination and/or breast imaging. ER- and PR- should meet one of the following criteria:
    • ≤ 10% cells stain positive, with weak intensity score (Allred score ≤ 3).
    • ≤ 1% cells stain positive, with weak or intermediate intensity score (Allred score ≤ 3).

    HER2 negative (not eligible for anti-HER2 therapy) will be defined as:

    • IHC 0, 1+ without ISH HER2/neu chromosome 17 ratio OR.
    • IHC 2+ and ISH HER2/neu chromosome 17 ratio non-amplified with ratio less than 2.0 and if reported average HER2 copy number < 6 signals/cells OR.
    • ISH HER2/neu chromosome 17 ratio non-amplified with ratio less than 2.0 and if reported average HER2 copy number < 6 signals/cells without IHC).

    NOTE: Patients that originally present with synchronous bilateral tumors are eligible provided both tumors are TNBC, and at least one of them fulfills the remainder eligibility criteria of the protocol.

  4. Patients must have completed neoadjuvant taxane +/- anthracycline. Patients must NOT have received cisplatin or carboplatin or capecitabine as part of their neoadjuvant therapy regimen.NOTE: Patients who received preoperative therapy as part of a clinical trial may enroll.
  5. Must have completed definitive resection of primary tumor.
    • Negative margins for both invasive and ductal carcinoma in situ (DCIS) are desirable, however patients with positive margins may enroll if the treatment team believes no further surgery is possible and patient has received radiotherapy. Patients with margins positive for lobular carcinoma in situ (LCIS) are eligible.
    • Either mastectomy or breast conserving surgery (including lumpectomy or partial mastectomy) is acceptable.
    • Sentinel node biopsy post neoadjuvant chemotherapy (i.e. at the time of definitive surgery) is allowed. Axillary dissection is encouraged in patients with lymph node involvement, but is not mandatory.
  6. Post neoadjuvant chemotherapy, patients must be found to have residual invasive cancer in the breast at the time of definitive surgery. Residual cancer is defined as a contiguous focus of residual invasive cancer, in the breast, measuring ≥ 1 cm in diameter, and with more than minimal cellularity, as per local pathologist determination.NOTE: The presence of ductal carcinoma in situ (DCIS) without invasion does not qualify as residual invasive disease in the breast.
  7. Post-mastectomy radiotherapy is required for all patients with the following:Primary tumor ≥ 5 cm (prior to neoadjuvant chemotherapy [clinically] or at the time of definitive surgery) or involvement of 4 or more lymph nodes at the time of definitive surgery.For patients with primary tumors < 5 cm or with < 4 involved lymph nodes prior to neoadjuvant chemotherapy and at the time of definitive surgery, provision of post-mastectomy radiotherapy is at the discretion of the treating physician.NOTE: Radiation of regional nodal basins is at the discretion of the treating radiation oncologist. Patients enrolled in clinical trials addressing local therapy after neoadjuvant chemotherapy are allowed to enroll.
  8. Breast radiotherapy (whole breast or partial) is required for patients who underwent breast-conserving therapy, including lumpectomy or partial mastectomy.
  9. Adequate bone marrow and organ function based on the following tests. Laboratory values must be obtained within 8 weeks prior to screening for protocol therapy.
  10. No stage IV (metastatic) disease, however no specific staging studies are required in the absence of symptoms or physical exam findings that would suggest distant disease.
  11. No clinically significant infections as judged by the treating investigator.
  12. Patients with active ≥ CTCAE v.4 grade 2 neuropathy are ineligible.
  13. Adjuvant chemotherapy after surgery other than that specified in this protocol is not allowed. LHRH agonists and adjuvant bisphosphonate or denosumab use is allowed.
  14. Patients must have archived formalin-fixed paraffin-embedded (FFPE) tumor tissue specimen from the residual disease on the definitive surgical specimen available for PAM50 analysis for stratification.
  15. Tumor tissue specimen from the definitive surgery has been collected and is ready to ship to the ECOG-ACRIN Central Biorepository and Pathology Facility (CBPF) within 21 weeks post-surgery.

Eligibility Criteria for Randomization (Step 1):

  1. Must have PAM50 analysis by digital mRNA quantitation on the formalin-fixed paraffin-embedded tumor tissue specimen (FFPE) of the residual disease in the breast or axilla resected at the time of definitive surgery completed. Date notified of eligibility per central PAM50 analysis:
  2. ECOG Performance Status 0 or 1 within 2 weeks prior to randomization.
  3. Patients must have completed adjuvant radiotherapy ≥ 2 weeks prior to randomization.
  4. Patients must have completed treatment with any investigational agent ≥ 30 days prior to randomization.
  5. Patients must be randomized within 24 weeks from surgery.
  6. Adequate bone marrow and organ function based on the following tests.

Genesys Hurley Cancer Institute

302 Kensington Avenue
Flint, MI 48503

810-762-8226 | 888-762-8675

Genesys Health System
Hurley Medical Center
Michigan Cancer Consortium

Newsletter

Ⓒ 2018 Genesys Hurley Cancer Institute | All Rights Reserved.

Cart

Cart